These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
236 related items for PubMed ID: 36878411
1. In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020. Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, Motyl MR, Hawser SP, Sahm DF. Int J Antimicrob Agents; 2023 May; 61(5):106772. PubMed ID: 36878411 [Abstract] [Full Text] [Related]
2. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital. Weber C, Schultze T, Göttig S, Kessel J, Schröder A, Tietgen M, Besier S, Burbach T, Häussler S, Wichelhaus TA, Hack D, Kempf VAJ, Hogardt M. Microbiol Spectr; 2022 Oct 26; 10(5):e0169722. PubMed ID: 36190424 [Abstract] [Full Text] [Related]
3. Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020. Lob SH, Estabrook MA, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, Sahm DF. Int J Infect Dis; 2022 Dec 26; 125():250-257. PubMed ID: 36244599 [Abstract] [Full Text] [Related]
4. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections. Ruedas-López A, Alonso-García I, Lasarte-Monterrubio C, Guijarro-Sánchez P, Gato E, Vázquez-Ucha JC, Vallejo JA, Fraile-Ribot PA, Fernández-Pérez B, Velasco D, Gutiérrez-Urbón JM, Oviaño M, Beceiro A, González-Bello C, Oliver A, Arca-Suárez J, Bou G. Antimicrob Agents Chemother; 2022 Feb 15; 66(2):e0206721. PubMed ID: 34930034 [Abstract] [Full Text] [Related]
5. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020. Karlowsky JA, Lob SH, DeRyke CA, Hilbert DW, Wong MT, Young K, Siddiqui F, Motyl MR, Sahm DF. Antimicrob Agents Chemother; 2022 May 17; 66(5):e0018922. PubMed ID: 35491836 [Abstract] [Full Text] [Related]
6. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China. Yu W, Zhang H, Zhu Y, Jia P, Xu Y, Yang Q. Int J Antimicrob Agents; 2023 Apr 17; 61(4):106741. PubMed ID: 36736928 [Abstract] [Full Text] [Related]
7. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D. Antimicrob Agents Chemother; 2018 Mar 17; 62(3):. PubMed ID: 29263073 [Abstract] [Full Text] [Related]
8. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021. Lee YL, Ko WC, Hsueh PR. Int J Antimicrob Agents; 2023 Aug 17; 62(2):106867. PubMed ID: 37244423 [Abstract] [Full Text] [Related]
9. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019. Karlowsky JA, Lob SH, Khan A, Chen WT, Woo PCY, Seto WH, Ip M, Leung S, Wong QW, Chau RWY, DeRyke CA, Young K, Motyl MR, Sahm DF. J Med Microbiol; 2022 Apr 17; 71(4):. PubMed ID: 35451945 [Abstract] [Full Text] [Related]
10. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK. Int J Antimicrob Agents; 2018 Feb 17; 51(2):181-189. PubMed ID: 28993143 [Abstract] [Full Text] [Related]
11. Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa. Gill CM, Nicolau DP, ERACE-PA Global Study Group. J Antimicrob Chemother; 2022 Dec 23; 78(1):252-256. PubMed ID: 36411249 [Abstract] [Full Text] [Related]
12. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar. Sid Ahmed MA, Abdel Hadi H, Hassan AAI, Abu Jarir S, Al-Maslamani MA, Eltai NO, Dousa KM, Hujer AM, Sultan AA, Soderquist B, Bonomo RA, Ibrahim EB, Jass J, Omrani AS. J Antimicrob Chemother; 2019 Dec 01; 74(12):3497-3504. PubMed ID: 31504587 [Abstract] [Full Text] [Related]
13. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. Sader HS, Castanheira M, Duncan LR, Mendes RE. Int J Infect Dis; 2021 Dec 01; 113():279-281. PubMed ID: 34670144 [Abstract] [Full Text] [Related]
14. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021). Sader HS, Mendes RE, Arends SJR, Carvalhaes CG, Shortridge D, Castanheira M. Int J Antimicrob Agents; 2023 Apr 01; 61(4):106744. PubMed ID: 36738849 [Abstract] [Full Text] [Related]
15. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. Shortridge D, Castanheira M, Pfaller MA, Flamm RK. Antimicrob Agents Chemother; 2017 Jul 01; 61(7):. PubMed ID: 28483953 [Abstract] [Full Text] [Related]
16. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary. O'Neall D, Juhász E, Tóth Á, Urbán E, Szabó J, Melegh S, Katona K, Kristóf K. Acta Microbiol Immunol Hung; 2020 Mar 26; 67(1):61-65. PubMed ID: 32208923 [Abstract] [Full Text] [Related]
17. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. Gill CM, Aktaþ E, Alfouzan W, Bourassa L, Brink A, Burnham CD, Canton R, Carmeli Y, Falcone M, Kiffer C, Marchese A, Martinez O, Pournaras S, Satlin M, Seifert H, Thabit AK, Thomson KS, Villegas MV, Nicolau DP, ERACE-PA Global Study Group. Eur J Clin Microbiol Infect Dis; 2021 Dec 26; 40(12):2533-2541. PubMed ID: 34291323 [Abstract] [Full Text] [Related]
18. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. Fraile-Ribot PA, Cabot G, Mulet X, Periañez L, Martín-Pena ML, Juan C, Pérez JL, Oliver A. J Antimicrob Chemother; 2018 Mar 01; 73(3):658-663. PubMed ID: 29149337 [Abstract] [Full Text] [Related]
19. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018). Cantón R, Loza E, Arcay RM, Cercenado E, Castillo FJ, Cisterna R, Gálvez-Benítez L, González Romo F, Hernández-Cabezas A, Rodríguez-Lozano J, Suárez-Barrenechea AI, Tubau F, Díaz-Regañón J, López-Mendoza D, SMART-Spain Working Group. Rev Esp Quimioter; 2021 Jun 01; 34(3):228-237. PubMed ID: 33645948 [Abstract] [Full Text] [Related]
20. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. Giani T, Arena F, Pollini S, Di Pilato V, D'Andrea MM, Henrici De Angelis L, Bassetti M, Rossolini GM, Pseudomonas aeruginosa Working Group. J Antimicrob Chemother; 2018 Mar 01; 73(3):664-671. PubMed ID: 29216350 [Abstract] [Full Text] [Related] Page: [Next] [New Search]